


STANDARD VAPE CORPORATION

FINANCIAL REPORT FOR THE PERIOD ENDED MARCH 31, 2020



Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines
STANDARD VAPE CORPORATION

A Nevada Corporation
4664 Susan Drive
Bethlehem, PA 18017
(201) 220-8734
<http://www.standardtobacco.com/>
info@standard-vape.com
SIC Code - 2100

Quarterly Report For the Period Ending:
March 31, 2020 (the "Reporting Period")

As of March 31, 2020, the end of the reporting period, the number of shares outstanding of our Common Stock was: 442,784,410.

As of December 31, 2019, the end of the prior reporting period, the number of shares outstanding of our Common Stock was: 26,308,700.

As of December 31, 2019, the end of our latest fiscal year, the number of outstanding shares of our Common Stock was: 26,308,700.

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: No: (Double-click and select "Default Value" to check)

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: No:

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

Please note that effective January 31, 2020 FINRA approved the Company's name change from Xuan Wu International Group Holding Company to Standard Vape Corporation and the name change took effect.

Date and state (or jurisdiction) of incorporation (also describe any changes to incorporation since inception, if applicable) Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Incorporated in Nevada on December 29, 2008 as Xuan Wu International Group Holding Company. The Articles of Incorporation have been amended as follows:

On February 22, 2018 the Issuer amended its Articles to increase its authorized capital stock to two billion shares, par value \$0.0001 per share and designated 1,990,000,000 shares as a sole class of common and 10,000,000 shares as preferred stock to be further designated from time to time in the sole discretion of the Board of Directors;

On May 3, 2018, the Issuer designated 300,000 shares of preferred as Class A Class A Preferred Convertible having a conversion ratio of 2500 shares of common stock for each converted share of Class A Preferred Stock; and each Class A Preferred share has the voting rights equivalent to the rights of 2500 shares of common stock.

On May 29, 2019, the Issuer designated 100,000 shares of Class B Preferred Stock, each Class B Preferred share is convertible into ten shares of common stock and each share has the voting power of 10 shares of common stock and each share has a liquidation preference of \$1.00. On the same date the Issuer designated 100,000 shares of Class C Preferred Stock, each Class C Preferred share is convertible into 50 shares of common stock and each share has the voting power of 50 common shares and each share has a liquidation preference of \$10.00 per share.

On October 15, 2019 the Issuer file an amendment changing its name to Standard Vape Corporation effective upon FINRA approval.

Issuer is active.

Has the issuer or any of its predecessors ever been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:

2. Shares Outstanding

The stated par value of common and preferred shares is \$0.0001

	March 31, 2020	December 31, 2019	Change
Common Shares			
Security Symbol	SVAP	SVAP	
CUSIP	85423F106	85423F106	
Authorized:	1,990,000,000	1,990,000,000	
Outstanding:	442,784,410	26,308,700	416,475,710
Freely Tradable (public float):	4,966,200	4,966,200	0
Number of record holders:	78	69	
# of beneficial holders owning at least 100 shares:	78	69	

Class A Preferred Shares

Security Symbol	None	None	
CUSIP	None	None	
Authorized:	300,000	300,000	
Outstanding:	92,625	250,000	(157,375)
Freely Tradable (public float):	N/A	N/A	
Number of record holders:	11	15	(4)
# of beneficial holders owning at least 100 shares:	11	15	(4)

Class B Preferred Shares

Security Symbol	None	None	
CUSIP	None	None	
Authorized:	100,000	100,000	
Outstanding:	25,000	25,000	-
Freely Tradable (public float):	N/A	N/A	
Number of record holders:	1	1	-
# of beneficial holders owning at least 100 shares:	1	1	-

Class C Preferred Shares

Security Symbol	None	None	
CUSIP	None	None	
Authorized:	100,000	100,000	
Outstanding:	0	0	0
Freely Tradable (public float):	N/A	N/A	
Number of record holders:	0	0	0
# of beneficial holders owning at least 100 shares:	0	0	0

Undesignated Preferred Shares

Security Symbol	None	None	
CUSIP	None	None	
Authorized:	9,500,000	9,500,000	
Outstanding:	0	0	0
Freely Tradable (public float):	N/A	N/A	
Number of record holders:	0	0	0

The Transfer agent is:
V Stock Transfer,
LLC 18 Lafayette
Place
Woodmere, NY 11598
Telephone: 212-828-8436
info@vstocktransfer.com

Is the Transfer Agent registered under the Exchange Act? Yes: No:

List any restrictions of on transfer of security: Rule 144 on 437,818,200 restricted shares

Describe any trading suspension orders issued by the SEC in past 12 months: None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On March 26, 2019, the Company sold its trademarks to its Licensee M&D Distributors, Inc. and acquired Nano Vape Corporation (NVC or Nano Vape). Nano Vape is engaged in the development of proprietary vaping technology. The terms of the acquisition resulted in John Fruhmenn returning his 300,000 shares of Class A Preferred Stock to Treasury and the issuance of 250,000 shares of the Class A Preferred Stock to the shareholders of Nano Vape in exchange for all issued and outstanding securities of Nano Vape. John Fruhmenn resigned as director of the Company and was replaced by Melvin Ehrlich. John Fruhmenn remains as President. The result of this acquisition was a change in control.

On April 19, 2019, the Company divested the business of Xuan Wu International Group, Inc. Please note that effective 1/31/2020 FINRA approved the Company's request to change its name to Standard Vape Corp. from Xuan Wu International Group Holding Company.

3. A. Issuance History

<u>Number of Shares</u>	<u>Security</u>
<u>Outstanding 1/1/2017</u>	
17,482,500	Common stock
0	Preferred Stock Class A
0	Preferred Stock Class B
0	Preferred Stock Class C
0	Undesignated Preferred Stock

There were twenty-nine common stock issuances/transactions during the past two years, including seventeen during the first quarter of 2020:

Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/Entity Shares were issued to (entities must have individual with voting/investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted as of this filing?	Exemption Registration Type
4/25/2018	New Issuance	850,000	Common	0.00	Yes	Off Balance D.O.O. / Beograd Vracar	Debt Conversion	Unrestricted	Rule 144 Sec. 4(a)(1)
4/30/2018	New Issuance	850,000	Common	0.00	Yes	Bryce Boucher	Debt Conversion	Unrestricted	Rule 144 Sec. 4(a)(1)
6/8/2018	New Issuance	850,000	Common	0.00	Yes	Chrysalis Management, LLC / George Matarazzo	Debt Conversion	Unrestricted	Rule 144 Sec. 4(a)(1)
7/17/2018	New Issuance	856,200	Common	0.00	Yes	Anika Zeimke	Debt Conversion	Unrestricted	Rule 144 Sec. 4(a)(1)
7/23/2018	New Issuance	950,000	Common	0.00	Yes	Trend D.O.O. / Igor Bonderenko	Debt Conversion	Unrestricted	Rule 144 Sec. 4(a)(1)
8/30/2018	New Issuance	90,000	Common	0.00	Yes	Daniel Z. Johnson	Stock Based Compensation	Unrestricted	Rule 144 Sec. 4(a)(1)
9/17/2018	New Issuance	850,000	Common	0.00	Yes	Drew C Fidler	Debt Conversion	Unrestricted	Rule 144 Sec. 4(a)(1)
1/22/2019	New Issuance	500,000	Common	0.00	Yes	Ann C. Copeland	Debt Conversion	Restricted	None
1/22/2019	New Issuance	500,000	Common	0.00	Yes	Diane Fruhmann	Debt Conversion	Restricted	None
1/22/2019	New Issuance	1,000,000	Common	0.00	Yes	Kathryn Fruhmann	Debt Conversion	Restricted	None
1/22/2019	New Issuance	500,000	Common	0.00	Yes	Rosellen M. Castellano	Debt Conversion	Restricted	None
10/7/2019	New Issuance	1,000,000	Common	0.00	Yes	Jenny Holman	Debt Conversion	Restricted	None
2/20/2020	New Issuance	137,500,000	Common	0.00	Yes	Daniel Fisher	Pref A Conversion	Restricted	None
2/20/2020	New Issuance	61,875,000	Common	0.00	Yes	Roger L. Fidler	Pref A Conversion	Restricted	None
2/26/2020	New Issuance	9,144,860	Common	0.00	Yes	Bradley W. Fidler	Debt Conversion	Restricted	None
2/29/2020	New Issuance	17,960	Common	0.00	Yes	Ann C. Copeland	Debt Conversion	Restricted	None

Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting/ investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted as of this filing?	Exemption Registration Type
2/29/2020	New Issuance	273,170	Common	0.00	Yes	Annika Zimke	Debt Conversion	Restricted	None
2/29/2020	New Issuance	1,464,650	Common	0.00	Yes	Bryce Boucher	Debt Conversion	Restricted	None
2/29/2020	New Issuance	273,170	Common	0.00	Yes	Chrysalis Management, LLC / George Matarazzo	Debt Conversion	Restricted	None
2/29/2020	New Issuance	17,960	Common	0.00	Yes	Diane Fruhmann	Debt Conversion	Restricted	None
2/29/2020	New Issuance	35,920	Common	0.00	Yes	Jennifer S. Holman	Debt Conversion	Restricted	None
2/29/2020	New Issuance	35,920	Common	0.00	Yes	Kathryn Fruhmann	Debt Conversion	Restricted	None
2/29/2020	New Issuance	1,449,300	Common	0.00	Yes	Off Balance D.O.O. / Beograd Vracar	Debt Conversion	Restricted	None
2/29/2020	New Issuance	17,960	Common	0.00	Yes	Rosellen M. Castellano	Debt Conversion	Restricted	None
2/29/2020	New Issuance	1,307,340	Common	0.00	Yes	Trend D.O.O. / Igor Bonderenko	Debt Conversion	Restricted	None
3/2/2020	New Issuance	69,062,500	Common	0.00	Yes	Dr. Mel Ehrlich	Pref A Conversion	Restricted	None
3/2/2020	New Issuance	62,500,000	Common	0.00	Yes	Elizabeth Ehrlich Kellogg	Pref A Conversion	Restricted	None
3/2/2020	New Issuance	62,500,000	Common	0.00	Yes	James Ehrlich	Pref A Conversion	Restricted	None
3/5/2020	New Issuance	9,000,000	Common	0.00	Yes	EW Partners Ltd/Oliver Templeton	Debt Conversion	Restricted	None

There were eighteen preferred stock issuances/transactions during the past two years:

Date of Transaction	Transaction type (e.g. new issuance, cancellations, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of Shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted as of this filing?	Exemption Registration Type
5/3/2018	New issuance	300,000	Preferred A	0.10	No	John F. Fruhmann	Stock Based Compensation	Restricted	Sec.4(2) Rule 504
3/28/2019	Returned to Treasury	-300,000	Preferred A	-	No	John F. Fruhmann*	Facilitate Change of Control	Restricted	Sec.4(2) Rule 504
3/28/2019	New Issuance	55,250	Preferred A	0.90	No	Dr. Mel Ehrlich	Acquisition of Nano Vape Corp	Restricted	Sec.4(2) Rule 504
3/28/2019	New Issuance	24,750	Preferred A	0.90	No	Roger L. Fidler	Acquisition of Nano Vape Corp	Restricted	Sec.4(2) Rule 504
3/28/2019	New Issuance	7,500	Preferred A	0.90	No	Dr. Mahantesh Navati	Acquisition of Nano Vape Corp	Restricted	Sec.4(2) Rule 504
3/28/2019	New Issuance	5,000	Preferred A	0.90	No	Girish Mavelli	Acquisition of Nano Vape Corp	Restricted	Sec.4(2) Rule 504
3/28/2019	New Issuance	2,500	Preferred A	0.90	No	Jyothishree T. Jayadeva	Acquisition of Nano Vape Corp	Restricted	Sec.4(2) Rule 504
3/28/2019	New Issuance	25,000	Preferred A	0.90	No	Elizabeth Kellogg	Acquisition of Nano Vape Corp	Restricted	Sec.4(2) Rule 504
3/28/2019	New Issuance	25,000	Preferred A	0.90	No	Daniel Ehrlich	Acquisition of Nano Vape Corp	Restricted	Sec.4(2) Rule 504
3/28/2019	New Issuance	25,000	Preferred A	0.90	No	James Ehrlich	Acquisition of Nano Vape Corp	Restricted	Sec.4(2) Rule 504
3/28/2019	New Issuance	5,000	Preferred A	0.90	No	Murray Froikin	Acquisition of Nano Vape Corp	Restricted	Sec.4(2) Rule 504
3/28/2019	New Issuance	2,500	Preferred A	0.90	No	Alan Alfieri	Acquisition of Nano Vape Corp	Restricted	Sec.4(2) Rule 504
3/28/2019	New Issuance	5,000	Preferred A	0.90	No	Moise Mehraban	Acquisition of Nano Vape Corp	Restricted	Sec.4(2) Rule 504
3/28/2019	New Issuance	5,000	Preferred A	0.90	No	Paul Barbooie	Acquisition of Nano Vape Corp	Restricted	Sec.4(2) Rule 504
3/28/2019	New Issuance	5,000	Preferred A	0.90	No	Waleed Abuzeid	Acquisition of Nano Vape Corp	Restricted	Sec.4(2) Rule 504
3/28/2019	New Issuance	2,500	Preferred A	0.90	No	Americo Graziosi	Acquisition of Nano Vape Corp	Restricted	Sec.4(2) Rule 504
3/28/2019	New Issuance	55,000	Preferred A	0.90	No	Dan Fisher	Acquisition of Nano Vape Corp	Restricted	Sec.4(2) Rule 504
7/11/2019	New Issuance	25,000	Preferred B	1.00	No	Chrysalis Management, GmbH/George Matarazzo	Cash	Restricted	Regulation S

Shares Outstanding
On March 31, 2020

Ending Balance
Common: 442,784,410
Preferred Class A 92,625
Preferred Class B 25,000

	# of Common Shares Held	# of Preferred Class A Shares Held	# of Preferred Class B Shares Held
Shares at beginning of the year	26,308,700	250,000	25,000
Shares Issuances during the year	416,475,710	-0-	-0-
Share Redemption during the year	-0-	(157,375)	-0-
Shares at the end of the year	442,784,410	92,625	25,000

* The Preferred Stock had no market price at dates of issuance.

Please note Mr. Fruhmann returned 300,000 shares as part of the Nano Vape Corp Acquisition.

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
January 16, 2009	-0-	1,124	-0-	June 16, 2017	Debt converted divided by \$0.001	Pivo Associates, Inc/Richard Oravec	Advance of Funds for companies Expenses
June 17, 2009	8,621.06	20,000	6,034	June 17, 2017	Debt converted divided by \$0.001	Pivo Associates, Inc/Richard Oravec	Advance of Funds for companies Expenses
June 24, 2009	-0-	3,415	-0-	June 24, 2016	Debt converted divided by \$0.001	Pivo Associates, Inc/Richard Oravec	Advance of Funds for companies Expenses
July 13, 2009	3,500	3,500	2,235	July 15, 2014	Debt converted divided by \$0.001	Pivo Associates, Inc/Richard Oravec	Advance of Funds for companies Expenses

4. Financial Statements

A. The following financial statements were prepared in accordance with:

US GAAP

IFRS

B. The financial statements for this reporting period were prepared by:

John DellaDonna CPA

No relationship to Issuer

The Issuer is providing unaudited consolidated financial statements for the periods ending March 31, 2020 and December 31, 2019.

A. Consolidated Balance Sheets

B. Consolidated Statements of Operations

C. Consolidated Statements of Cash Flows; and

D. Consolidated Statements of Changes in Shareholders Deficit

E. Financial Notes

These unaudited consolidated financial statements are incorporated by reference herein and attached as Exhibit 1.

5. Issuer's Business, Products and Services.

Forward-Looking Statements

This section of the report includes a number of forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934 that reflect our current views with respect to future events and financial performance. Forward looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this report. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions. Although we believe the expectations reflected in these forward-looking statements are reasonable, such expectations cannot guarantee future results, levels of activity, performance or achievements.

Forward-looking statements included in this report and all subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. The forward-looking statements speak only as of the date made, other than as required by law, and we undertake no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise.

ISSUER'S BUSINESS, PRODUCTS AND SERVICES:

Standard Vape Corporation., ("Standard") was incorporated on December 30, 2008 under the laws of the State of Nevada as Xuan Wu International Group Holding Company and changed its name to Standard Vape Corporation on 1/31/2020.

On 12/13/17, the Company decided to return its Chinese wholly owned subsidiary, Xuan Wu International Group Inc., to its former owners. The return of that business to the former owners was accomplished in 2019. The Company acquired a tobacco licensing company that profits from an uptick in interest in classic pipe smoking brands. On 3/28/19 Xuan Wu entered into a definitive sale contract with Bethlehem IP Holdings, Inc., an entity controlled by the Swedish Tobacco Group

("STG"). STG acquired the entire catalogue of trademarks of XNWU's wholly owned subsidiary The Standard Tobacco Company of Pennsylvania, Ltd. for cash consideration of Fifty Thousand Dollars. The catalogue of trademarks includes iconic trade names *War Horse*, *John Cotton's*, *Bengal Slices*, *Dobie's* and *Murray's*. These formerly British pipe tobacco brands were revived and sold by Pipes and Cigars under the Standard Tobacco name. Standard Tobacco retains the rights to use these marks on certain products outside the tobacco industry if it should choose to do so. On the same date, 3/28/19, the Company acquired Nano Vape Corporation ("Nano"), which was formed in 2019 to exploit vaping technology; a portion of which is the subject of a recently filed provisional patent application. Nano intends to unveil a novel vaping device based upon the technology in the first quarter of 2020.

Xuan Wu International Group Holding Company ("XNWU" or the "Company") through that its subsidiary Nano Vape Corporation ("Nano Vape") entered into a product development and license agreement with a related party, NMB Therapeutics, Inc. ("NMB"), a Florida corporation, on May 6, 2019. In exchange for \$50,000, NMB will develop a nicotine-laden nanoparticle ("NanoNOxTM"). The utilization of NanoNOxTM is hoped to allow the reduction of the amount of nicotine required to produce the same physical sensation during vaping with the delivery of less nicotine and even less residual nicotine being left in the lungs of the user. The Agreement also provides Nano Vape with an exclusive worldwide license to manufacture and market the nicotine nanoparticles paying a five percent (5%) royalty to NMB. To date NMB has not delivered the patent specifications for NanoNOxTM either to the management or its patent attorneys. It is anticipated that this will be delivered in Q1 of 2020 with a resulting provisional patent filed at the same time or as soon as practical. Nano Vape Corporation was formed in 2019 to exploit vaping technology that is expected to eliminate some, and lessen more, of the objections that have been posed by the United States Food and Drug Administration ("FDA") concerning vaping. Nano Vape is developing a novel vaping device based upon the technology developed by Mel Ehrlich, Ph.D., presently sole director and officer of Nano Vape, and his team. The device should eliminate the need for heating the vaping fluid and will eliminate the danger of fire present with lithium batteries contained in the existing vaping devices without lessening performance and reduce exposure to heavy metals by the elimination of the traditional heating element employed by e-cigarettes.

To date the company has caused to be built a formal functioning prototype of the device based around the designs of the filed provisional patent. The device incorporates all the features and benefits described above namely:

- No heating coils thus the nicotine solution is turned into an aerosol as opposed to the industry norm of heating the solution. This has certain health benefits since when heated in traditional e-cigarettes vaping fluid is changed producing certain byproducts which it has been suggested could be injurious to the user's health.
- The absence of a heating coil may reduce a further health risk known as 'popcorn lung' which is caused by the vapor collecting minute particles of heavy metal from the heating coil as the steam of the heated vape fluid is breathed into the user's lungs.
- The device contains no lithium battery which has been shown to be a fire hazard, unstable and has been known to explode in other commercially available e-cigarettes resulting in injuries to the user. The Standard Vape product relies on drawing its power from a charged capacitor that stores the electricity that runs the vaporizing device.
- The vape solution itself is a mixture of nicotine salts, distilled water and a small amount of

organic glycerin which is inhaled to deliver the sensation of smoking and deliver an amount of nicotine in the same range as a commercial cigarette. NMB is based at The Albert Einstein College of Medicine in the Bronx, New York. The team at NMB is led by Dr. Mel Ehrlich along with Mahantesh Navati, Ph.D., and is developing some of the more innovative applications for the use of nanoparticles in areas as diverse as cosmetics and dentistry. Dr. Navati commented: “We are very excited about developing this new use of nanoparticles and being able to further reduce the amount of nicotine consumed during the vaping experience without reducing the benefits of vaping versus combustible tobacco.”

To date the Company has had very early stage discussions with Juul Laboratories, Inc. and exchanged various NDA’s in the late summer of 2019. These discussions are early stage and ongoing with Standard Vape’s management and scientific team but have largely been delayed by current events with the FDA and the ‘Vaping Crisis’ which has been well covered in the media and has caused substantial disruption to Juul Laboratories. In the most recent quarterly period, the Company has signed NDA’s with two large European based tobacco conglomerates with a view to either a joint venture, licensing agreement or outright sale of Standard Vape Corporation’s technology. These discussions continue to be early stage and are hoped to develop after delivery and review of Standard Vape’s prototyped device.

In April, 2020, the Issuer formed Neo Virucide, Inc., a Wyoming corporation, as a wholly owned subsidiary. Neo Virucide then entered into an Exclusive Worldwide License and Product Development Agreement with NMB Therapeutics, Inc., a related party, thereby acquiring the marketing rights to NanoNOx™, a proprietary nanoparticle formed to deliver nitric oxide upon being inhaled. Neo Virucide is moving toward preclinical animal testing with the aim of submitting a preIND to the FDA this year and commencing clinical trials in 2021. The treatment of COVID-19 and other respiratory conditions is the aim of the trials. Neo Virucide is negotiating with a major university medical clinic to act as principal investigator in an investigator initiated human clinical trial. NanoNOx™ is thought to act as a vasodilator and may have antiviral and antimicrobial activity.

Date; State; and Jurisdiction of Incorporation:

Xuan Wu International Group Holding Co., Inc., (the “Company”) was incorporated under the laws of Nevada on December 30, 2008. Effective 1/31/2020 FINRA approved the Company’s request to change its name to Standard Vape Corp. from Xuan Wu International Group Holding Company.

Issuer’s Primary and Secondary SIC Codes:

2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products.

Fiscal Year:

The Company’s fiscal year ends on December 31.

Products:

The Company, through its Nano Vape Corporation subsidiary, acquired the rights to a brand new and improved e-cigarette developed by Dr. Mel Ehrlich. The Company also owns the marketing rights, subject to an 8% royalty and payment of \$500,000 in initial fees, of NanoNOx™.

Marketing Opportunity

Dr. Mel Ehrlich's development of technology which we believe will enable production of an entirely new form of e-cigarette that will deliver nicotine without recourse to the present form of nicotine solution but plans to use a form of nicotine having increased bioavailability and less residual nicotine in the lungs allowing for lower nicotine use producing the same physical inhalation benefit. A further enhancement is the elimination of the industry standard lithium battery that powers heating vaping fluid and replacing it with a different type of power supply which may reduce the risk of the e-cigarette catching fire or exploding whilst being used by the consumer. A provisional patent application has been filed in the U.S on this new and novel device with plans to expand the territorial scope of the application to one with worldwide protection during 2019. It is also envisaged that the new product can be used to deliver medicinal compounds if they are capable of being absorbed through the lung tissue lining particularly CBD.

We intend to move to commercial production as quickly as possible (once we have received the necessary regulatory approvals), using a contract manufacturer, although the possibility of technology sales or licensing does exist and is being pursued.

6. Describe the Issuer's Facilities.

The Company is provided with office space by its President at no charge. The Company conducts its research and development work at a small laboratory space located at the Albert Einstein College of Medicine in the Bronx, NY.

7. Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information regarding any person or entity owning 5% or more of the issuer, as well as any officer, and any director of the company, regardless of the number of shares they own. **If any listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information of an individual representing the corporation or entity in the note section.**

Name & Address *	Affiliation with Company (e.g. Officer/Director/Owner of over 5%)	Residential Address (City / State Only)	# Common Shares Held	# of Preferred Class A Shares Held	% of Common Owned	% of Preferred Class A Owned
John F. Fruhmann	President, CFO, & Secretary	Bethlehem, PA	10,722,200	0	2.42%	0.00%
Dr. Mel Ehrlich,	Director	Roslyn, NY	69,062,500	27,625	15.60%	29.82%
Daniel Fisher		Pleasant Hill, CA	137,500,000	-	31.05%	0.00%
Roger L. Fidler		Lutz, FL	61,875,000	-	13.97%	0.00%
Elizabeth Kellogg *		Roslyn, NY	62,500,000	-	14.12%	0.00%
Daniel Ehrlich *		Roslyn, NY	-	25,000	0.00%	26.99%
Girish Navelli		Bronx, NY	-	5,000	0.00%	5.40%
Dr. Mahantesh Navati		Bronx, NY	-	7,500	0.00%	8.10%
Murray Froikin		New York, NY	-	5,000	0.00%	5.40%
Moise Mehraban		Great Neck, NY	-	5,000	0.00%	5.40%
Paul Barbooie		Bronx, NY	-	5,000	0.00%	5.40%
Waleed Abuzeid		Bronx, NY	-	5,000	0.00%	5.40%

* Children of Melvin Ehrlich

Separately, Chrysalis** Management GmbH, controlled by George Matarazzo, of Düsseldorf Germany owns 100% of Preferred Class B shares.

John F. Fruhmann, President, Chief Financial Officer & Secretary

Upon graduating from Fairleigh Dickenson University in 1974 with an MBA in Finance, Mr. Fruhmann worked at Pfizer Inc./Minerals Technologies Inc. for over 30 years in various sales and marketing management positions. He retired in February 2008 as Director of Sales. In 2009 Mr. Fruhmann served on of the founding Directors of Lauren's Hope Foundation, Inc. (www.laurenshopefoundation.com), a 501(c)3 charitable organization whose mission is to assist children born with brain injuries and their families.

Dr. Mel Ehrlich, Director

Dr. Ehrlich served as CEO of Cyttest Labs, Inc., which develops optical scanners using ultraviolet (UV) light for spectrum analysis and a pattern recognition computer to measure and analyze human body cell parameters. One application of this technology was for early detection of lung cancer, analyzing exfoliated lung cells. From 2003 to 2008, he served as Chairman and CEO of Efficient Energy Conversion Systems, Inc. (EECS). EECS has designed and patented significant improvements

in oil burners and internal combustion (IC) engines. From 2002 to 2003, Dr. Ehrlich served as President and Chief Operating Officer of ARTES Medical, Inc., a San Diego-based medical device company with a one-of-a-kind patented microsphere technology for permanent soft-tissue bulking, particularly of deep facial wrinkles. From 1998 to 2002, Dr. Ehrlich was Vice President of SerOptix, Inc., Woburn, MA, for which he initiated its fluorescence spectroscopy program, which resulted in a technology for the rapid detection of infectious diseases in transfusion blood such as HIV, Hepatitis C, among others.

Dr. Ehrlich served as a Research Professor of Physics at Yeshiva University where he directed a staff of faculty and graduate students in a research program in non-invasive cardiology at the Albert Einstein College of Medicine, detecting and measuring low-level cardiac electrical activity. Both software and hardware were developed to provide a dynamic electrical map of patients' hearts to detect anomalies. The research effort was to determine whether these small anomalies could be indicative or predictive of heart disease.

He was President and Chairman of Nuclear Research Associates where he created and directed scientific programs in nuclear weapon phenomenology, primarily of the ELF portion of the electromagnetic spectrum, including effects on the earth's magnetosphere. Detection devices, developed and built, were installed and operated in a worldwide network for nuclear weapons detection and signal analysis (U.S. Joint Task Force 4 Pacific Operations, High Altitude Nuclear Device Testing, 1962). He is a member of the American Physical Society and New York Academy of Sciences. Dr. Ehrlich has had patents granted in areas as diverse as a thermodynamically pumped laser, scanning microspectrophotometer, photochromics, batteries, and thin film technology. He has published and presented papers on these and other subjects.

8. Legal/Disciplinary History:

A. Legal/Disciplinary History of the Officers and Directors and Control Persons

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses):

NONE

2. The entry of an order, judgment or decree, not subsequently suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities.

NONE

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding, or judgment has not been reversed, suspended or vacated.

NONE

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred or suspended or otherwise limited such person's involvement in any type of business or securities activities.

NONE

5. There are no pending or threatened legal proceedings.

9. Third Party Providers

Legal Counsel

Roger L. Fidler Attorney at Law
1522 Gardner Drive
Lutz, FL 33559
(201) 220-8734
(201) 464-7943(Fax)

Investor Relations Advisor

Keith Bayley Rogers & Co. Ltd
1 Royal Exchange Avenue
London, ENG EC3V 3LT
Brinsley.Holman@kbrl.co.uk
011-44-207-464-4090

Accountant

JDDACPA LLC
3131 Piedmont Ave
Suite 203
Atlanta, GA 30305
(404) 826-3902

10. Issuer Certification.

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities). The certifications shall follow the format below:
I, John Fruhmann certify that:

1. I have reviewed this quarterly disclosure statement of Standard Vape Corporation;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

6/30/2020

/s/ John Fruhmann

John Fruhmann

Principal Financial Officer:

I, John Fruhmann certify that:

1. I have reviewed this quarterly disclosure statement of Standard Vape Corporation;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

6/30/2020

/s/ John Fruhmann

John Fruhmann

**EXHIBIT I – UNAUDITED FINANCIAL STATEMENTS.
STANDARD VAPE CORPORATION**

CONSOLIDATED BALANCE SHEETS UNAUDITED

	3/31/2020	12/31/2019
ASSETS		
Current Assets		
Cash	\$ 376	\$ 1,228
Total current assets	376	1,228
Other Assets		
Trademarks	225,000	225,000
Total fixed and other assets	225,000	225,000
TOTAL ASSETS	\$ 225,376	\$ 226,228
LIABILITIES AND SHAREHOLDERS' DEFICIENCY		
Current liabilities		
Convertible notes payable	\$ 20,390	\$ 43,341
Accrued expenses	256,819	182,388
Total current liabilities	277,209	225,729
Long-term liabilities		
Derivative liability	734,061	753,338
Total long-term liabilities	734,061	753,338
Total liabilities	1,011,270	979,067
SHAREHOLDERS' DEFICIENCY		
Class A Preferred Stock; par value \$0.0001; authorized 300,000 shares; as of March 31, 2020, and December 31, 2019, there are 92,625 and 250,000 outstanding, respectively	9	25
Class B Preferred Stock; par value \$0.0001; authorized 100,000 shares; as of March 31, 2020, and December 31, 2019, there are 25,000 and 25,000 outstanding, respectively	3	3
Class C Preferred Stock; par value \$0.0001; authorized 100,000 shares; as of March 31, 2020, and December 31, 2019, there are 0 and 0 outstanding, respectively	-	-
Undesignated Preferred Stock; par value \$0.0001; authorized 9,500,000 shares; as of March 31, 2020, and December 31, 2019, there are 0 and 0 outstanding, respectively	-	-
Common Stock; par value \$0.0001; 1,990,000,000 shares authorized; as of March 31, 2020, and December 31, 2019, there are 442,784,410 and 26,308,700 shares outstanding, respectively	44,278	2,631
Additional paid-in capital	587,320	605,913
Accumulated deficit	(1,417,504)	(1,361,411)
Total shareholders' deficiency	(785,894)	(752,839)
TOTAL LIABILITIES & SHAREHOLDERS' DEFICIENCY	\$ 225,376	\$ 226,228

The accompanying notes are an integral part of these consolidated financial statements

STANDARD VAPE CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
UNAUDITED

	Three Months Ended March 31,	
	2020	2019
Revenue	\$ -	\$ 2,188
Operating Expenses		
General and administrative expenses	75,283	8,502
Total Operating Expenses	75,283	8,502
Operating Income/(Loss)	(75,283)	(6,314)
Other Income (Expense)		
Loss/(Gain) in change in fair value of derivative liability	(19,277)	1,454,359
Loss on disposal of intellectual property	-	188,537
Interest expense	87	538
Total Other Income (Expense)	19,190	(1,643,434)
Income/(Loss) from Continuing Operations	(56,093)	(1,649,748)
Provision for taxes	-	-
Net income/(Loss) Applicable to Common Shares	\$ (56,093)	\$ (1,649,748)
 Net income/(Loss) per share		
Basic	\$ (0.00)	\$ (0.07)
Diluted	\$ (0.00)	\$ (0.04)
 Shares used in computing net income/(loss) per share:		
Basic	184,504,713	24,725,367
Diluted	204,894,773	45,028,367

The accompanying notes are an integral part of these consolidated financial statements

STANDARD VAPE CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
UNAUDITED

	Three Months ended March 31,	
	2020	2019
Cash Flows From Operating Activities		
Net income (loss)	\$ (56,093)	\$ (1,649,748)
(Gain) / loss on derivative liability	(19,277)	1,454,359
Loss on disposal of intellectual property	-	188,537
Adjustments to reconcile net loss to net cash provided by operating activities.		
(Increase) decrease accounts receivable	-	500
Increase (decrease) accrued expenses	74,431	2,500
Increase (decrease) accrued interest	(15,769)	(922)
Net cash provided (used) in operating activities	<u>(16,708)</u>	<u>(4,774)</u>
Cash Flows from Financing Activities		
Notes payable	(7,182)	-
Share issuance	23,038	1,460
Net cash provided by Financing activities	<u>15,856</u>	<u>1,460</u>
Cash Flows from Investing Activities		
Net cash provided by Investing activities	-	-
NET CHANGE IN CASH	<u>(852)</u>	<u>(3,314)</u>
Cash at beginning of period	1,228	22,881
Net cash at end of period	<u>\$ 376</u>	<u>\$ 19,567</u>
SUPPLEMENTAL CASH FLOW INFORMATION		
Cash paid for income taxes	\$ -	\$ -
Cash paid for interest	\$ -	\$ -
NON CASH FINANCING AND INVESTING ACTIVITY		
Issuance of preferred stock for purchase of subsidiary	\$ -	\$ 225,000
Common stock issued for debt	\$ 23,038	\$ 2,500

STANDARD VAPE CORPORATION

STATEMENT OF CHANGES IN SHAREHOLDERS' DEFICIT UNAUDITED

Date	Shares		Amount		Additional Paid-in Capital	Retained Earnings	Shareholders' Equity
	Common	Preferred	Common	Preferred			
Balance, December 31, 2016	16,482,500	-	1,648	-	58,765	(2,632,671)	(2,572,258)
12/31/17							
Shares issued to buy The Standard Tobacco Company of Pennsylvania, Inc.	1,000,000	-	100	-	249,900	-	250,000
Net loss for the year ended December 31, 2017	-	-	-	-	-	(4,453,272)	(4,453,272)
Balance, December 31, 2017	17,482,500	-	1,748	-	308,665	(7,085,943)	(6,775,530)
Shares issued during 2018	5,326,200	300,000	533	30	42,009		42,572
Net income for the year ended December 31, 2018	-	-	-	-	-	3,561,349	3,561,349
Balance, December 31, 2018	22,808,700	300,000	2,281	30	350,674	(3,524,594)	(3,171,609)
Shares canceled		(300,000)		(30)	30	-	-
Shares issued during 2019	3,500,000	25,000	350	3	30,234	-	30,587
3/28/19							
Corporation	-	250,000	-	25	224,975	-	225,000
Net income for the year ended December 31, 2019	-	-	-	-	-	2,163,184	2,163,184
Balance, December 31, 2019	26,308,700	275,000	2,631	28	605,913	(1,361,410)	(752,838)
Shares issued during 2020	416,475,710	(157,375)	41,647	(16)	(18,593)	-	23,038
Net loss for the three months ended March 31, 2020	-	-	-	-	-	(56,094)	(56,094)
Balance, March 31, 2020	442,784,410	117,625	44,278	12	587,320	(1,417,504)	(785,894)

The accompanying notes are an integral part of these consolidated financial statements

STANDARD VAPE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION

The Company

The Corporation was formed on December 29, 2008 in the State of Nevada. Its initial authorized capital stock was 100,000,000 shares of common stock having a par value of \$0.001 per share; and, 20,000,000 shares of Preferred Stock having a par value of \$0.001 per share.

Simultaneously therewith the Corporation acquired Xuan Wu International Group, Inc. (Target), a Chinese corporation engaged in quarry operations. Pursuant to that acquisition of the Corporation exchanged 16,482,500 shares of common stock for all the issued and outstanding shares of Target. The Notice of Exchange was filed in Nevada on January 5, 2009. At that time control was vested in Jinhui Guo with 10,000,000 shares out of the 16,482,500 shares.

On November 1, 2017, Jinhui Guo resigned as sole officer and director of the Corporation and Roger Fidler became the sole officer and director of the Corporation.

On December 31, 2017 the Corporation acquired for 1,000,000 shares of the Corporation's common stock all the issued and outstanding shares of Standard. Mr. Fruhmann, who executed on behalf of The Standard Tobacco Company of Pennsylvania, Inc. (Standard), a Nevada corporation engaged in trademark licensing of trademarks acquired for formulations of tobacco that mimic the classic British brands which trademarks had been acquired by Standard. Simultaneously therewith, Roger Fidler resigned as the sole officer and director of the Corporation and John Fruhmann became the sole officer and director of the Corporation. On the same date, the Corporation agreed to return all shares of Target to Target's shareholders.

On February 22, 2018, voting control of the Corporation was vested in John Fruhmann by Jinhui Guo transferring 10,000,000 common shares to Mr. Fruhmann.

On February 22, 2018, the Corporation also increased its authorized capital stock to two billion (2,000,000,000) shares having a par value of \$0.0001 per share of which one billion nine hundred and ninety were shares of common stock and ten million shares were preferred stock.

On April 1, 2018, the Corporation released any ownership rights to the Target and returned all the Target's shares to Target shareholders. On May 3, 2018, the Corporation filed a Certificate of Designation designating 300,000 preferred shares as Class A Preferred Stock. These 300,000 shares of Class A Preferred Stock were issued to John Fruhmann and were recorded as stock-based compensation worth \$30,000. Kindly note that Mr. Fruhmann returned the 300,000 preferred shares on 3/28/19.

On June 11, 2018, the Corporation filed an Amendment to its Articles of Incorporation effecting a ten for one forward split of its common stock, to be effective three days after FINRA clears the Issuer Company-Related Corporate Action Notification. The approval of FINRA did not occur and hence the amendment has not and will not become effective.

On August 30, 2018, 90,000 shares were issued to a former officer, Daniel Z. Johnson, who furnished certain intellectual property to the Company, which we recorded as stock-based compensation worth \$4,500.

During the third quarter of 2018, a total of \$2,686 of a convertible note was converted into a total of 2,686,200 common shares. For the first quarter of 2019, a total of \$2,500 of a convertible note was converted into 2,500,000 common shares.

On 3/28/19 the Company issued 250,000 Class A Preferred Stock with a fair value of \$225,000 in order to acquire Nano Vape Corporation, a Wyoming company whose primary asset is a new type of e-cigarette. On 5/15/19 the Company designated 100,000 of its preferred shares as Class B Preferred

Stock that are convertible into 100 shares of common stock, carry a \$0.10 quarterly cumulative dividend payable from profits when realized, and are subject to a \$10.00 per share mandatory redemption price and liquidation preference. On 5/15/19 the Company designated 100,000 of its preferred shares as Class C Preferred Stock that are convertible into 500 shares of common stock.

To complete the realignment of the business Xuan Wu also entered into a definitive sale contract on 3/28/19 with Bethlehem IP Holdings, Inc., an entity controlled by the Swedish Tobacco Group (“STG”). STG will acquire the entire catalogue of trademarks of XNWU’s wholly owned subsidiary The Standard Tobacco Company of Pennsylvania, Ltd. for cash consideration of Fifty Thousand Dollars. The catalogue of trademarks includes iconic trade names War Horse, John Cotton’s, Bengal Slices, Dobie’s and Murray’s. These formerly British pipe tobacco brands were revived and sold by Pipes and Cigars under the Standard Tobacco name. Standard Tobacco retains the rights to use these marks on certain products outside the tobacco industry if it should choose to do so.

On July 11, 2019, the Company accepted \$25,000 Chrysalis Management, GmbH, in a Regulation S placement for 25,000 shares of its Class B Preferred Stock.

During the fourth quarter of 2019, \$1,000 of a convertible note was converted into a total of 1,000,000 common shares. During the first quarter of 2020, \$23,038 of convertible notes was converted into 23,038,210 common shares and 157,375 Preferred A shares were converted into 393,437,500 common shares.

Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in The United States of America and the rules and regulations of the Securities and Exchange Commission (“SEC”).

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Cash

Cash consists principally of currency on hand, and demand deposits at commercial banks. The Company had cash of \$376 on March 31, 2020 and \$1,228 on December 31, 2019.

Revenue Recognition

Revenues are recognized when the following revenue recognition criteria are met: (1) persuasive evidence of an arrangement exists; (2) there is a fixed or determinable price; (3) the product has been shipped and the customer takes ownership and assumes risk of loss; and (4) collectability of the resulting receivable is reasonably assured. These criteria are satisfied upon shipment of product, and revenues are recognized

Net Income or (Loss) Per Share of Common Stock

Basic and diluted loss per common share is based upon the weighted average number of common shares outstanding during the period computed under the provisions of Accounting Standards Codification subtopic 260-10, Earnings per Share (“ASC 260-10”). Diluted income (loss) per share includes the dilutive effects of common stock equivalents on an “as if converted” basis.

Goodwill

The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in acquisition transactions is classified as goodwill. In accordance with Statement No. 142, "Goodwill and Other Intangible Assets," the Company does not amortize goodwill, but performs impairment tests of the carrying value at least annually.

Intangible Assets

Intangible assets are stated at the lesser of cost or fair value less accumulated amortization.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period enacted. A valuation allowance is provided when it is more likely than not that a portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The benefit of tax positions taken or expected to be taken in the Company's income tax returns are recognized in the condensed financial statements if such positions are more likely than not of being sustained.

In accordance with ASC 740-10, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting this standard, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

Fair Value of Instruments

ASC 825-10, Financial Instruments requires disclosure of the fair value of certain financial instruments. The carrying value of cash, and accounts payable and accrued liabilities, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

The company follows ASC 820-10, Fair Value Measurements and Disclosures and Accounting Standards Codification subtopic 825-10, Financial Instruments ("ASC 825-10"), which permits entities to choose to measure many financial instruments and certain other items at fairvalue.

Recently Issued Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing

U.S. GAAP. As amended by the FASB in July 2015, the standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of ASU 2014-09 on our future financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), to provide guidance on recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements, specifically differentiating between different types of leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from all leases. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous GAAP. There continues to be a differentiation between finance leases and operating leases. However, the principal difference from previous guidance is that the lease assets and lease liabilities arising from operating leases should be recognized in the balance sheet. The accounting applied by a lessor is largely unchanged from that applied under previous GAAP. The amendments will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and early adoption is permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The modified retrospective approach includes a number of optional practical expedients that entities may elect to apply. These practical expedients relate to the identification and classification of leases that commenced before the effective date, initial direct costs for leases that commenced before the effective date, and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset. An entity that elects to apply the practical expedients will, in effect, continue to account for leases that commence before the effective date in accordance with previous GAAP unless the lease is modified, except that lessees are required to recognize a right-of-use asset and a lease liability for all operating leases at each reporting date based on the present value of the remaining minimum rental payments that were tracked and disclosed under previous GAAP. The Company is currently evaluating the impact of these amendments on its financial statements.

In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, to clarify the implementation guidance on principal versus agent considerations and address how an entity should assess whether it is the principal or the agent in contracts that include three or more parties. The effective date and transition requirements for these amendments are

the same as the effective date and transition requirements of ASU 2014-09 (discussed above). The Company is currently evaluating the impact of these amendments on its financial statements.

In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, to clarify the following two aspects of Topic 606: 1) identifying performance obligations, and 2) the licensing implementation guidance. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). The Company is currently evaluating the impact of these amendments on its financial statements.

NOTE 2 - GOING CONCERN

Under ASC 205-40, we have the responsibility to evaluate whether conditions and/or events raise substantial doubt about our ability to meet our future financial obligations as they become due within one year after the date that the financial statements are issued. As required by this standard, our evaluation shall initially not take into consideration the potential mitigating effects of our plans that have not been fully implemented as of the date the financial statements are issued.

In performing the first step of this assessment, we concluded that the following conditions raise substantial doubt about our ability to meet our financial obligations as they become due. We have a history of net losses for the period ended March 31, 2020; we had a cumulative net loss of \$1,417,504. For the period ended March 31, 2020, we had negative working capital of \$276,833. We expect to continue to incur negative working capital until such time as our operating segments generate sufficient cash to finance our operations and debt service requirements.

In performing the second step of this assessment, we are required to evaluate whether our plans to mitigate the conditions above alleviate the substantial doubt about our ability to meet our obligations as they become due within one year after the date that the financial statements are issued. Our future plans include securing additional funding sources that may include establishing corporate partnerships, establishing licensing revenue agreements, issuing additional convertible debentures and issuing public or private equity securities, including selling common stock through an at-the-market facility (ATM).

There is no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available through external sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material effect on the business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or they will not have a significant dilutive effect on the Company's existing shareholders.

The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern.

NOTE 3 — CORPORATE RESTRUCTURING

Disposition of Subsidiary

The Company sold its catalog of British tobacco trademarks on 3/28/19 to the Swedish Tobacco Group and recorded a loss of \$188,537.

Disposition of Trademarks

To complete the realignment of the business Xuan Wu also entered into a definitive sale contract on 3/28/19 with Bethlehem IP Holdings, Inc., an entity controlled by the Swedish Tobacco Group ("STG"). STG will acquire the entire catalogue of trademarks of XNWU's wholly owned subsidiary The Standard Tobacco Company of Pennsylvania, Ltd. for cash consideration of Fifty Thousand Dollars. The catalogue of trademarks includes iconic trade names *War Horse*, *John Cotton's*, *Bengal Slices*, *Dobie's* and *Murray's*. These formerly British pipe tobacco brands were revived and sold by Pipes and Cigars under the Standard Tobacco name. Standard Tobacco retains the rights to use these marks on certain products outside the tobacco industry if it should choose to do so.

NOTE 4 - PROVISION FOR INCOME TAXES

The Company files income tax returns in the United States federal jurisdiction and certain state jurisdictions. We did not provide any current or deferred U.S. Federal Income Tax provision or benefit

for any of the periods presented because we have experienced operating losses since our date of incorporation. Accounting for the Uncertainty in Income Taxes when it is more likely than not that a tax asset cannot be realized through future income, the Company must allow for this future tax benefit. We provided full valuation allowance on the net deferred asset, consisting of net operating loss carry forwards, because management has determined that it is more likely than not that we will not earn income sufficient to realize the deferred assets during the carry forward period.

NOTE 5 – ACQUISITION OF NANO VAPE CORPORATION

On 3/28/19 the Company issued 250,000 Class A Preferred Stock with a fair value of \$225,000 in order to acquire Nano Vape Corporation, whose primary asset is a new type of e-cigarette. Under the acquisition method of accounting, the total purchase price was allocated to net tangible and intangible assets based on their estimated fair values.

NOTE 6 – CONVERTIBLE NOTES PAYABLE

The Company has entered into multiple convertible notes payable agreements with a minority stockholder of the Company which had advanced funds to pay the Company's expenses. Each note carries a separately dated promissory note that bears interest of 6%. The note can be converted at any time by the holder into common shares of the company at the rate of \$.001/share.

On January 16, 2009, the Company executed a Convertible Note payable to Pivo Associates, Inc. in the principal amount of \$1,124 in exchange for \$1,124 cash. Pivo Associates, Inc. who is the registered holder hereof and its successors and assigns (the "Holder" or Holders"), the principal sum of \$1,124 on the Maturity Date, (January 16, 2021) and (except as otherwise herein stated) to pay interest on the principal sum outstanding at the rate of six percent (6%) per annum due and payable on the Maturity Date with interest in arrears. Accrual of interest on the outstanding principal amount, payable in cash or Common Stock (defined hereinafter) at the Holder's option, shall commence with respect to each of the amounts set forth on the date of this Note and shall continue until payment in full of the outstanding principal amount has been made or duly provided for. The holder of this Note is entitled, at his option, pursuant to the Agreement of the Company at the time of each of the Original Note amounts was incurred, at any time commencing on the date first written above, to convert all or a portion of the original principal face amount and/or interest of this Note into shares (the "Conversion Shares") of common stock (the "Common Stock") in the Company, at a conversion ratio (the "Conversion Ratio") which shall equal the dollar amount Holder is electing to convert divided by the par value, which is \$0.001, of the Company's Common Stock as of the date of this Note. This note can be converted into approximately 1,864,000 shares as of 12/31/19. However, at no time shall so much of this Note be converted so that the Holder(s) shall own at any time given more than 9.9% of the Company's then issued and outstanding common stock. This note was converted during the first quarter of 2020 into common shares.

On June 17, 2009, the Company executed a Convertible Note payable to Pivo Associates, Inc. in the principal amount of \$20,000 in exchange for \$20,000 cash. Pivo Associates, Inc. who is the registered holder hereof and its successors and assigns (the "Holder" or Holders"), the principal sum of \$20,000 on the Maturity Date, (June 17, 2017) and (except as otherwise herein stated) to pay interest on the principal sum outstanding at the rate of six percent (6%) per annum due and payable on the Maturity Date with interest in arrears. Accrual of interest on the outstanding principal amount, payable in cash or Common Stock (defined hereinafter) at the Holder's option, shall commence with respect to each of the amounts set forth on the date of this Note and shall continue until payment in full of the outstanding principal amount has been made or duly provided for. The holder of this Note is entitled, at his option, pursuant to the Agreement of the Company at the time of each of the Original Note amounts was incurred, at any time commencing on the date first written above, to convert all or a portion of the original principal face amount and/or interest of this Note into shares (the "Conversion

Shares”) of common stock (the “Common Stock”) in the Company, at a conversion ratio (the “Conversion Ratio”) which shall equal the dollar amount Holder is electing to convert divided by the par value, which is \$0.001, of the Company’s Common Stock as of the date of this Note. This note can be converted into approximately 18,584,000 shares as of 12/31/19. However, at no time shall so much of this Note be converted so that the Holder(s) shall own at any time given more than 9.9% of the Company’s then issued and outstanding common stock. This note is in default. During the second quarter of 2018, a total of \$2,550 of this note was converted into a total of 2,550,000 common shares. During the third quarter of 2018, a total of \$2,686 of a convertible note was converted into a total of 2,686,200 common shares. For the first quarter of 2019, a total of \$2,500 of a convertible note was converted into 2,500,000 common shares. During the fourth quarter of 2019, \$1,000 of the convertible note was converted into a total of 1,000,000 common shares. \$8,621.06 plus interest of \$6,034 of the note is still outstanding.

On June 24, 2009, the Company executed a Convertible Note payable to Pivo Associates, Inc. in the principal amount of \$3,415 in exchange for \$3,415 cash. Pivo Associates, Inc. who is the registered holder hereof and its successors and assigns (the “Holder” or Holders”), the principal sum of \$3,415 on the Maturity Date, (June 24, 2016) and (except as otherwise herein stated) to pay interest on the principal sum outstanding at the rate of six percent (6%) per annum due and payable on the Maturity Date with interest in arrears. Accrual of interest on the outstanding principal amount, payable in cash or Common Stock (defined hereinafter) at the Holder’s option, shall commence with respect to each of the amounts set forth on the date of this Note and shall continue until payment in full of the outstanding principal amount has been made or duly provided for. The holder of this Note is entitled, at his option, pursuant to the Agreement of the Company at the time of each of the Original Note amounts was incurred, at any time commencing on the date first written above, to convert all or a portion of the original principal face amount and/or interest of this Note into shares (the “Conversion Shares”) of common stock (the “Common Stock”) in the Company, at a conversion ratio (the “Conversion Ratio”) which shall equal the dollar amount Holder is electing to convert divided by the par value, which is \$0.001, of the Company’s Common Stock as of the date of this Note. This note can be converted into approximately 5,569,000 shares as of 12/31/19. However, at no time shall so much of this Note be converted so that the Holder(s) shall own at any time given more than 9.9% of the Company’s then issued and outstanding common stock. This note was converted during the first quarter of 2020 into common shares.

On July 13, 2009, the Company executed a Convertible Note payable to Pivo Associates, Inc. in the principal amount of \$3,500 in exchange for \$3,500 cash. Pivo Associates, Inc. who is the registered holder hereof and its successors and assigns (the “Holder” or Holders”), the principal sum of \$3,500 on the Maturity Date, (July 15, 2014) and (except as otherwise herein stated) to pay interest on the principal sum outstanding at the rate of six percent (6%) per annum due and payable on the Maturity Date with interest in arrears. Accrual of interest on the outstanding principal amount, payable in cash or Common Stock (defined hereinafter) at the Holder’s option, shall commence with respect to each of the amounts set forth on the date of this Note and shall continue until payment in full of the outstanding principal amount has been made or duly provided for. The holder of this Note is entitled, at his option, pursuant to the Agreement of the Company at the time of each of the Original Note amounts was incurred, at any time commencing on the date first written above, to convert all or a portion of the original principal face amount and/or interest of this Note into shares (the “Conversion Shares”) of common stock (the “Common Stock”) in the Company, at a conversion ratio (the “Conversion Ratio”) which shall equal the dollar amount Holder is electing to convert divided by the par value, which is \$0.001, of the Company’s Common Stock as of the date of this Note. This note can be converted into approximately 5,702,000 shares as of 12/31/19. However, at no time shall so much of this Note be converted so that the Holder(s) shall own at any time given more than 9.9% of the Company’s then issued and outstanding common stock. This note is in default. \$3,500 plus interest of \$2,235 of the note is still outstanding.

NOTE 8 - DERIVATIVE LIABILITY

The derivative liability consisted of:

	<u>3/31/20</u>	<u>12/31/2019</u>
Convertible Promissory Note dated January 16, 2009 payable to Pivo Associates, Inc. including accrued interest of \$0 and \$1,433, respectively.	\$ -	\$ 44,899
Convertible Promissory Note dated June 17, 2009 payable to Pivo Associates, Inc. including accrued interest of \$6,034 and \$14,172, respectively.	527,595	444,139
Convertible Promissory Note dated June 24, 2009 payable to Pivo Associates, Inc. including accrued interest of \$0 and \$4,263, respectively.	-	133,606
Convertible Promissory Note dated July 13, 2009 payable to Pivo Associates, Inc. including accrued interest of \$2,234 and \$4,170, respectively.	<u>206,466</u>	<u>130,694</u>
Total derivative liability	<u>\$ 734,061</u>	<u>\$ 753,338</u>

The embedded conversion option of the convertible notes qualifies for derivative accounting under ASC 815-15, Derivatives and Hedging. The Company records the fair value of the conversion price of the convertible debentures in accordance with ASC 815, Derivatives and Hedging. The fair value of the derivative liability is revalued on each balance sheet date or upon conversion of the underlying convertible debenture into equity with corresponding gains and losses recorded in the consolidated statement of operations. The fair value of the derivative liability as of March 31, 2020 and December 31, 2019 was determined using the Black Scholes Option Pricing Model with the following assumptions:

Dividend yield:	0
Volatility	10 %
Risk free rate:	0.116 %

NOTE 9 – SUBSEQUENT EVENTS

None